{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:23:10Z","timestamp":1787840590854,"version":"build-2784847793"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To present results from the Vitreo Retina Society\u2013India (VRSI) 2024 Preference and Trends Survey, focusing on polypoidal choroidal vasculopathy (PCV) and diabetic retinopathy (DR) management practices among Indian vitreoretinal surgeons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Responses to a 62-item questionnaire, distributed to all VRSI members over email via Google Forms, were collected over 6 weeks in July-\u2013August 2024. Data were analyzed using descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 289 members participated in the survey. The majority of respondents preferred multimodal imaging for the diagnosis of PCV (44.68%) and aflibercept for initiation of therapy (63.12%). Respondents preferred a loading dose with a pro-re-nata regimen (46.45%) and a switch after three injections in cases of suboptimal response (57.45%), with a strong preference for switching to brolucizumab (63.93%). Pan-retinal photocoagulation was the predominantly preferred treatment modality for all cases of proliferative DR, with an increased preference for combining it with antivascular endothelial growth factor (anti-VEGF) in cases with high-risk characteristics. For centre-involving diabetic macular edema, ranibizumab biosimilars (40.79%) in a by pro re nata regimen (53.21%) were preferred. Respondents would switch to steroids (54.48%) for suboptimal response after three anti-VEGF injections (91.04%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The current preferences in the management of PCV and DR among Indian vitreoretinal surgeons are reported here. The results of this survey will assist fellow practitioners in understanding contemporary real-world practices in relation to established literature and in developing appropriate guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_927_25","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T16:12:47Z","timestamp":1761667967000},"page":"1581-1589","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Management of Polypoidal choroidal vasculopathy and diabetic retinopathy: Practice patterns amongst vitreoretinal surgeons of India\u2014A VRSI survey"],"prefix":"10.4103","volume":"73","author":[{"given":"Manavi D","family":"Sindal","sequence":"first","affiliation":[{"name":"Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mahendrakar","sequence":"additional","affiliation":[{"name":"Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshat","family":"Kothari","sequence":"additional","affiliation":[{"name":"Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudit","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Smt Kanuri Santhamma Center for Vitreoretinal Diseases, Anant Bajaj Retina Institute, L V Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyansh","family":"Mishra","sequence":"additional","affiliation":[{"name":"Vitreoretinal and Ocular Oncology Services, Sankara Eye Hospitals, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivraj","family":"Tagare","sequence":"additional","affiliation":[{"name":"Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Vitreoretinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Pondicherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"Vitreoretinal and Oncology Services, Sankara Eye Hospitals, Sankara Eye Hospital, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"R2-20260419","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.4103\/ijo.IJO_2877_20","article-title":"Vitreoretinal Society of India practice pattern survey 2020: Surgical retina","volume":"69","author":"Sheth","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R3-20260419","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4103\/ijo.IJO_2573_20","article-title":"Vitreoretinal Society of India practice pattern survey 2020: Medical retina","volume":"69","author":"Sheth","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R4-20260419","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.4103\/ijo.IJO_2985_21","article-title":"Updated guidelines for the management of polypoidal choroidal vasculopathy: Recommendations from the Indian Polypoidal Choroidal Vasculopathy Panel and the Vitreoretinal Society of India","volume":"70","author":"Sheth","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"R5-20260419","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"R6-20260419","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: Two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R7-20260419","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000518235","article-title":"Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC study: A randomized clinical trial","volume":"245","author":"Silva","year":"2022","journal-title":"Ophthalmologica"},{"key":"R8-20260419","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1177\/11206721211014717","article-title":"One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy","volume":"31","author":"Rouvas","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R9-20260419","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20260419","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/bjophthalmol-2021-319090","article-title":"Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK","volume":"106","author":"Ogura","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R11-20260419","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ajo.2012.08.002","article-title":"Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy","volume":"155","author":"Gemmy Cheung","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R12-20260419","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/IAE.0000000000003921","article-title":"Risk of exudation in eyes with nonexudative polypoidal choroidal vasculopathy","volume":"44","author":"Son","year":"2024","journal-title":"Retina"},{"key":"R13-20260419","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ajo.2014.12.020","article-title":"Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator","volume":"159","author":"Kimura","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R14-20260419","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.oret.2017.07.012","article-title":"Pneumatic displacement of submacular hemorrhage with subretinal air and tissue plasminogen activator: Initial United States experience","volume":"2","author":"Sharma","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R15-20260419","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archopht.1968.00980050585004","article-title":"A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. IV. Diabetic retinal angiopathy","volume":"80","author":"Gass","year":"1968","journal-title":"Arch Ophthalmol"},{"key":"R16-20260419","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.oret.2020.01.004","article-title":"Vitreoretinal interface slab in OCT angiography for detecting diabetic retinal neovascularization","volume":"4","author":"Hirano","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R17-20260419","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00417-018-3992-y","article-title":"Comparison between wide-angle OCT angiography and ultra-wide field fluorescein angiography for detecting non-perfusion areas and retinal neovascularization in eyes with diabetic retinopathy","volume":"256","author":"Sawada","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R18-20260419","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"R19-20260419","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS Study)","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"key":"R20-20260419","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.4103\/ijo.IJO_1265_21","article-title":"A Delphi method based consensus statement for surgical management of proliferative diabetic retinopathy in India","volume":"69","author":"Sengupta","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R21-20260419","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40123-021-00416-4","article-title":"Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation","volume":"11","author":"Ratra","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R22-20260419","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ophtha.2011.09.058","article-title":"Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema","volume":"118","author":"Aiello","year":"2011","journal-title":"Ophthalmology"},{"key":"R23-20260419","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"R24-20260419","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","article-title":"Outcomes with as-needed ranibizumab after initial monthly therapy","volume":"122","author":"Boyer","year":"2015","journal-title":"Ophthalmology"},{"key":"R25-20260419","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41433-023-02667-w","article-title":"Suboptimal outcomes and treatment burden of anti-vascular endothelial growth factor treatment for diabetic macular oedema in phakic patients","volume":"38","author":"Rennie","year":"2024","journal-title":"Eye"},{"key":"R26-20260419","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.4103\/ijo.IJO_1469_21","article-title":"Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement","volume":"69","author":"Giridhar","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R27-20260419","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","article-title":"Diabetic macular edema and diode subthreshold micropulse laser","volume":"130","author":"Lois","year":"2023","journal-title":"Ophthalmology"},{"key":"R28-20260419","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s10792-021-01923-w","article-title":"Is immediate treatment necessary for diabetic macular edema after pars plana vitrectomy for tractional complications of proliferative diabetic retinopathy?","volume":"41","author":"Behera","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R29-20260419","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.survophthal.2019.04.008","article-title":"Surgical management of diabetic tractional retinal detachments","volume":"64","author":"Iyer","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R30-20260419","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/IAE.0000000000003052","article-title":"Silicone oil versus perfluoropropane gas tamponade during vitrectomy for tractional retinal detachment or fibrous proliferation: A randomized clinical trial","volume":"41","author":"Rush","year":"2021","journal-title":"Retina"},{"key":"R31-20260419","first-page":"CD008214","article-title":"Anti\u2010vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy","volume":"2015","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R32-20260419","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1442-9071.2011.02575.x","article-title":"Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: The effect of perioperative anticoagulation and antiplatelet agents","volume":"39","author":"Fabinyi","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"key":"R33-20260419","first-page":"1362","article-title":"Antiplatelets and anticoagulants in vitreoretinal surgery: A systematic review","volume":"13","author":"Confalonieri","year":"2023","journal-title":"Life (Basel)"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_927_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:25:35Z","timestamp":1787837135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_927_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_927_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2025-04-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}